Wedbush Initiates Coverage On Spyre Therapeutics with Outperform Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has initiated coverage on Spyre Therapeutics with an Outperform rating and set a price target of $45.
September 04, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush has initiated coverage on Spyre Therapeutics with an Outperform rating and a price target of $45, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $45 by a reputable analyst can lead to increased investor interest and potential upward movement in the stock price. This is a strong positive signal for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100